Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBIT Margin (2016 - 2026)

Wave Life Sciences (WVE) has disclosed EBIT Margin for 12 consecutive years, with 81.83% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin rose 46099.0% year-over-year to 81.83%; the TTM value through Mar 2026 reached 419.38%, down 36431.0%, while the annual FY2025 figure was 504.09%, 40215.0% down from the prior year.
  • EBIT Margin hit 81.83% in Q1 2026 for Wave Life Sciences, up from 606.49% in the prior quarter.
  • Across five years, EBIT Margin topped out at 11.51% in Q4 2024 and bottomed at 13648.77% in Q3 2022.
  • Average EBIT Margin over 5 years is 2081.51%, with a median of 205.98% recorded in 2023.
  • Year-over-year, EBIT Margin plummeted -1362789bps in 2022 and then soared 1365780bps in 2023.
  • Wave Life Sciences' EBIT Margin stood at 53.65% in 2022, then soared by 73bps to 14.57% in 2023, then surged by 179bps to 11.51% in 2024, then tumbled by -5368bps to 606.49% in 2025, then surged by 87bps to 81.83% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 81.83%, 606.49%, and 542.82% for Q1 2026, Q2 2025, and Q1 2025 respectively.